Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 14/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMC2 | O95347 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.37 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30521347 | 1.00 | OPRK1 (0.39) | OPRK1MAP2K2MAP2K1ABCB11NQO2 | |
| SCHEMBL31286477 | 0.83 | AKR1C3 (0.40) | MAP2K2MAP2K1ABCB11NQO2KDM4E | |
| SCHEMBL30520683 | 0.81 | ALDH1A1 (0.41) | NR4A2KDM4EEGLN1 | |
| SCHEMBL30521062 | 0.79 | EGLN1 (0.37) | NR4A2KDM4EEGLN1 | |
| SCHEMBL30242139 | 0.78 | ATR (0.39) | OPRK1 | |
| SCHEMBL23925396 | 0.78 | ATR (0.39) | OPRK1 | |
| SCHEMBL17910027 | 0.77 | KMT2A (0.37) | OPRK1NR4A2KDM4E | |
| SCHEMBL30733305 | 0.77 | MAP2K2 (0.42) | MAP2K2MAP2K1ABCB11NQO2NR4A2 | |
| SCHEMBL30073351 | 0.77 | ALDH1A1 (0.40) | KDM4E | |
| SCHEMBL30618046 | 0.77 | KMT2A (0.37) | OPRK1NR4A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024231852-A1 | SUBSTITUTED BIPHENYL COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-11-14 | — | — | WO | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109153643-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2022-06-21 | — | — | CN | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | OPRK1 2351/4885MAP2K2 1021/4885MAP2K1 1491/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | OPRK1 2351/4885MAP2K2 1021/4885MAP2K1 1491/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | OPRK1 2351/4885MAP2K2 1021/4885MAP2K1 1491/4885 |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | OPRK1 2351/4885MAP2K2 1021/4885MAP2K1 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.